Nutriband Inc. (NTRBW) Stock Price & Analysis
Nutriband Inc. (NTRBW) — price $0.55 (-68.21%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Nutriband Inc. · NTRBW
Nutriband Inc. is a biotechnology company focused on developing transdermal pharmaceutical products, with a primary focus on abuse-deterrent fentanyl patches. The company aims to provide clinicians and patients with safer and more effective pain management solutions.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.55 |
| Change on the day | -68.21% |
| 52-week range | $0.1745 – $2.99 |
| Shares traded on the day | 46.1K |
Price & events
Watch the NTRBW film — every key number, told as a short cinematic story
~2 min · open the film
What is Nutriband (NTRBW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nutriband Inc. (NTRBW) is the company analyzed here. It employs 3 people and is led by Gareth Sheridan. In Q2 FY2026 it reported revenue of $437,514 and net income of -$880,561.
What do the latest results show for Nutriband (NTRBW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $437,514. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $437,514 | -$880,561 | -$0.07 (diluted) |
| Q1 FY2026 | $433,399 | -$1M | -$0.10 (diluted) |
| Q4 FY2025 | $400,709 | -$968,059 | -$0.08 (diluted) |
| Q3 FY2025 | $346,058 | -$4M | -$0.32 (diluted) |
What are the financial strengths and risks for Nutriband (NTRBW)?
Short answer · as of
The distress and quality screens read Altman Z 33.66 · Piotroski F 3. Trailing ratios: current ratio 4.21 · earnings yield -7.8% · free-cash-flow yield -4.1%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Nutriband (NTRBW)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $95.41M · EPS 1.57 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $95.41M
- EPS estimate
- $1.57
Measured against a quoted price of $0.55 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Nutriband (NTRBW)?
Nutriband Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the NTRBW research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What does Nutriband Inc. do?
Nutriband Inc. is a biotechnology company that develops transdermal pharmaceutical products, with a primary focus on creating abuse-deterrent opioid formulations. The company also has a license agreement to develop RAMBAM Closed System Transfer Devices.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.55 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T13:44:23.577Z. | |
px.change | Change on the day | -68.21% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$1.18 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 46.1K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $437,514 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$880,561 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 0 sales, 12 other transactions · 3 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.1745 – $2.99 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 3 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Gareth Sheridan | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-10 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 33.66 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-09-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 4.21 · earnings yield -7.8% · free-cash-flow yield -4.1% | UNRECORDED | Stored key metrics — Captured 2026-10-02 · Expired observation | |
earn.estimates | Analyst estimates, next fiscal year | FY2027 revenue $95.41M · EPS 1.57 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2027 | $95.41M | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_eps | EPS estimate, FY2027 | $1.57 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.